Pacira Pharmaceuticals (PCRX) Set to Announce Earnings on Thursday

Pacira Pharmaceuticals (NASDAQ:PCRX) will post its quarterly earnings results before the market opens on Thursday, November 1st. Analysts expect Pacira Pharmaceuticals to post earnings of ($0.07) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, August 2nd. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.37. The company had revenue of $84.10 million during the quarter, compared to the consensus estimate of $77.53 million. Pacira Pharmaceuticals had a negative net margin of 3.64% and a negative return on equity of 0.39%. The firm’s revenue for the quarter was up 18.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.11) earnings per share. On average, analysts expect Pacira Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of PCRX stock opened at $49.00 on Wednesday. The stock has a market capitalization of $1.88 billion, a PE ratio of -84.48 and a beta of 1.87. The company has a debt-to-equity ratio of 0.98, a current ratio of 8.58 and a quick ratio of 7.79. Pacira Pharmaceuticals has a one year low of $26.95 and a one year high of $52.60.

PCRX has been the subject of several analyst reports. ValuEngine downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Canaccord Genuity set a $45.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, September 4th. Wedbush set a $85.00 price objective on shares of Pacira Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, August 6th. BMO Capital Markets raised their price objective on shares of Pacira Pharmaceuticals to $40.00 and gave the stock a “neutral” rating in a report on Thursday, August 2nd. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 4th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $48.00.

In other news, Director Mark A. Kronenfeld acquired 1,000 shares of the business’s stock in a transaction dated Tuesday, August 28th. The stock was bought at an average cost of $44.61 per share, for a total transaction of $44,610.00. Following the completion of the transaction, the director now owns 8,577 shares of the company’s stock, valued at $382,619.97. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Lauren Bullaro Riker sold 1,667 shares of the firm’s stock in a transaction that occurred on Wednesday, August 22nd. The shares were sold at an average price of $44.48, for a total transaction of $74,148.16. Following the completion of the transaction, the vice president now owns 10,474 shares of the company’s stock, valued at $465,883.52. The disclosure for this sale can be found here. Insiders have sold 40,502 shares of company stock valued at $1,913,864 in the last quarter. Company insiders own 5.90% of the company’s stock.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks

Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply